Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter?

We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant bacteremia versus VAN alone by using pooled data from two previously published observational studies (  = 156). Combo was inversely associated with persistent bact...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2019-03, Vol.63 (3)
Hauptverfasser: Dilworth, Thomas J, Casapao, Anthony M, Ibrahim, Omar M, Jacobs, David M, Bowers, Dana R, Beyda, Nicholas D, Mercier, Renee-Claude
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant bacteremia versus VAN alone by using pooled data from two previously published observational studies (  = 156). Combo was inversely associated with persistent bacteremia (adjusted odds ratio, 0.460; 95% confidence interval, 0.229 to 0.923). Acute kidney injury was more common with Combo than with VAN (18.9% and 7.6%, respectively; = 0.062).
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02211-18